

Product Information®  Information du Produit®


Biaxin XL – demonstrated to lead to fewer discontinuations vs. Biaxin BID¹



Biaxin XL's once-daily dosing has been shown to lead to fewer treatment discontinuations vs. Biaxin BID in patients with AMS¹

- Biaxin XL
- Biaxin BID

Discontinuations due to gastrointestinal or abnormal taste events.¹



Adapted from Murray JJ, et al., 2002.¹

¹ Phase III, randomized, double-blind, parallel-group, multicentre study on patients with acute maxillary sinusitis (AMS) receiving either immediate-release (Biaxin BID) (n=141) or extended-release clarithromycin (Biaxin XL) (n=142).

Biaxin XL (clarithromycin extended-release tablets) is indicated in the treatment of mild-to-moderate infections caused by susceptible strains of the designated microorganisms in the following diseases: **Community-acquired pneumonia (CAP)** due to *H. influenzae*, *H. parainfluenzae*, *M. catarrhalis*, *S. pneumoniae*, *C. pneumoniae* (TWAR), or *M. pneumoniae*; 7-day treatment. **Acute maxillary sinusitis (AMS)** due to *H. influenzae*, *M. catarrhalis*, or *S. pneumoniae*; 14-day treatment. **Acute bacterial exacerbation of chronic bronchitis (AECB)** due to *H. parainfluenzae*, *H. influenzae*, *M. catarrhalis*, *S. aureus*, or *S. pneumoniae*; 5-day or 7-day treatment. The efficacy and safety of Biaxin XL in treating other infections for which Biaxin BID and Pediatric Biaxin are approved have not been established. Most frequently reported adverse events were diarrhea (6%), abnormal taste (7%), and nausea (3%). Most of these events were described as mild to moderate in severity. Clarithromycin is contraindicated as concurrent therapy with astemizole, terfenadine, cisapride, pimozide, ergotamine, or dihydroergotamine.

Product monograph available upon request.

References: 1. Murray JJ, Solomon E, McClusky D, et al. Phase III, randomized, double-blind study of clarithromycin extended-release and immediate-release formulations in the treatment of adult patients with acute maxillary sinusitis. *Clin Ther* 2000;22(12):1421-32. 2. Biaxin Product Monograph. Abbott Laboratories, Limited. November 10, 2008.



www.abbott.ca
1-800-361-7852

© Abbott Laboratories, Limited
Saint-Laurent, Québec H4S 1Z1



Product Information®  Information du Produit®

HELP KIDS AT RISK OF ANAPHYLAXIS GET READY FOR BACK-TO-SCHOOL.

Help your EpiPen® patients be prepared this back-to-school season. Make sure your patients at risk of anaphylaxis have easy access to an EpiPen®. Go to www.EpiPen.ca for valuable resources for you and your patients, including:

- Your FREE EpiPen® HCP Training Kit
- Order additional FREE EpiPen® Trainers for your patients
- Important back-to-school resources



Product Information®  Information du Produit®

Coversyl® & Coversyl® Plus - NEW FORMAT!

Servier Canada is proud to announce the launch of bottles of 100 tablets. These formats are presently available for ordering at your designated wholesaler. Product order codes are indicated below. Pricing has been established at the same per pill price as the 30 tablet blister pack.

Wholesaler	Coversyl® 2mg	Coversyl® 4mg	Coversyl® 8mg	Coversyl® Plus
McKesson	807149	808485	808535	809475
AmerisourceBergen	SV00752	SV00702	SV00782	SV00762
McMahon	340406	344291	340539	345538

Please contact your Servier Representative if you have product-specific questions. For further information regarding orders, please feel free to contact your wholesaler or Servier Canada at 1-888-902-9700 (ext.4250).

Product Information®  Information du Produit®

REIMBURSEMENT INFORMATION FOR GLEEVEC* (imatinib mesylate) IS NOW AVAILABLE ON WWW.DRUGCOVERAGE.ORG

This web site provides access to specific information on coverage through private insurance, provincial / territorial and federal plans. It also provides the appropriate reimbursement criteria, prior authorization / special authorization request forms, letters and instructions for submitting claims and preparing special authorization requests for coverage.

GLEEVEC* DINs: 02253275, 02253283

Please refer to the GLEEVEC* Product Monograph for indications, contraindications, warnings, precautions and dosing guidelines.

*GLEEVEC is a registered trademark of Novartis.

FREE CLASSIFIED ADVERTISING FOR PHARMACISTS



FAX :
1-800-420-3616



EMAIL:
contact@ipharmadirect.com

Visit us at
www.ipharmadirect.com



www.abbott.ca
1-800-361-7852



Biaxin XL – Once daily for AECB, CAP and AMS^{2†}

[†] AECB: acute exacerbation of chronic bronchitis; CAP: community-acquired pneumonia; AMS: Acute maxillary sinusitis.



© Abbott Laboratories, Limited
Saint-Laurent, Québec H4S 1Z1

Product monograph available upon request.

